154 related articles for article (PubMed ID: 29161698)
1. A Comparison of Three Methods for the Detection of Circulating Tumor Cells in Patients with Early and Metastatic Breast Cancer.
Politaki E; Agelaki S; Apostolaki S; Hatzidaki D; Strati A; Koinis F; Perraki M; Saloustrou G; Stoupis G; Kallergi G; Spiliotaki M; Skaltsi T; Lianidou E; Georgoulias V; Mavroudis D
Cell Physiol Biochem; 2017; 44(2):594-606. PubMed ID: 29161698
[TBL] [Abstract][Full Text] [Related]
2. Heterogeneous atypical cell populations are present in blood of metastatic breast cancer patients.
Lustberg MB; Balasubramanian P; Miller B; Garcia-Villa A; Deighan C; Wu Y; Carothers S; Berger M; Ramaswamy B; Macrae ER; Wesolowski R; Layman RM; Mrozek E; Pan X; Summers TA; Shapiro CL; Chalmers JJ
Breast Cancer Res; 2014 Mar; 16(2):R23. PubMed ID: 24602188
[TBL] [Abstract][Full Text] [Related]
3. Comparison of three molecular assays for the detection and molecular characterization of circulating tumor cells in breast cancer.
Strati A; Kasimir-Bauer S; Markou A; Parisi C; Lianidou ES
Breast Cancer Res; 2013 Mar; 15(2):R20. PubMed ID: 23497487
[TBL] [Abstract][Full Text] [Related]
4. Detection of Circulating Tumor Cells in Breast Cancer Patients Using Cytokeratin-19 Real-Time RT-PCR.
Park HS; Han HJ; Lee S; Kim GM; Park S; Choi YA; Lee JD; Kim GM; Sohn J; Kim SI
Yonsei Med J; 2017 Jan; 58(1):19-26. PubMed ID: 27873491
[TBL] [Abstract][Full Text] [Related]
5. Effect of front-line chemotherapy on circulating CK-19 mRNA-positive cells in patients with metastatic breast cancer.
Georgoulias V; Apostolaki S; Bozionelou V; Politaki E; Perraki M; Georgoulia N; Kalbakis K; Kotsakis A; Xyrafas A; Agelaki S; Mavroudis D
Cancer Chemother Pharmacol; 2014 Dec; 74(6):1217-25. PubMed ID: 25344760
[TBL] [Abstract][Full Text] [Related]
6. Circulating tumor cells (CTCs) detected by triple-marker EpCAM, CK19, and hMAM RT-PCR and their relation to clinical outcome in metastatic breast cancer patients.
Zhao S; Yang H; Zhang M; Zhang D; Liu Y; Liu Y; Song Y; Zhang X; Li H; Ma W; Zhang Q
Cell Biochem Biophys; 2013 Mar; 65(2):263-73. PubMed ID: 22990361
[TBL] [Abstract][Full Text] [Related]
7. Detection of cytokeratin 19, human mammaglobin, and carcinoembryonic antigen-positive circulating tumor cells by three-marker reverse transcription-PCR assay and its relation to clinical outcome in early breast cancer.
Chen Y; Zou TN; Wu ZP; Zhou YC; Gu YL; Liu X; Jin CG; Wang XC
Int J Biol Markers; 2010; 25(2):59-68. PubMed ID: 20586026
[TBL] [Abstract][Full Text] [Related]
8. Comparison of circulating tumor cells (CTC) in peripheral blood and disseminated tumor cells in the bone marrow (DTC-BM) of breast cancer patients.
Schindlbeck C; Andergassen U; Hofmann S; Jückstock J; Jeschke U; Sommer H; Friese K; Janni W; Rack B
J Cancer Res Clin Oncol; 2013 Jun; 139(6):1055-62. PubMed ID: 23525580
[TBL] [Abstract][Full Text] [Related]
9. Clinical relevance of circulating CK-19mRNA-positive tumour cells before front-line treatment in patients with metastatic breast cancer.
Androulakis N; Agelaki S; Perraki M; Apostolaki S; Bozionelou V; Pallis A; Kalbakis K; Xyrafas A; Mavroudis D; Georgoulias V
Br J Cancer; 2012 Jun; 106(12):1917-25. PubMed ID: 22669159
[TBL] [Abstract][Full Text] [Related]
10. Enrichment with anti-cytokeratin alone or combined with anti-EpCAM antibodies significantly increases the sensitivity for circulating tumor cell detection in metastatic breast cancer patients.
Deng G; Herrler M; Burgess D; Manna E; Krag D; Burke JF
Breast Cancer Res; 2008; 10(4):R69. PubMed ID: 18687126
[TBL] [Abstract][Full Text] [Related]
11. Circulating tumor cells in patients with breast cancer: monitoring chemotherapy success.
Ušiaková Z; Mikulová V; Pintérová D; Brychta M; Valchář J; Kubecová M; Tesařová P; Bobek V; Kološtová K
In Vivo; 2014; 28(4):605-14. PubMed ID: 24982230
[TBL] [Abstract][Full Text] [Related]
12. Detection of cytokeratin-19 mRNA-positive cells in the peripheral blood and bone marrow of patients with operable breast cancer.
Daskalaki A; Agelaki S; Perraki M; Apostolaki S; Xenidis N; Stathopoulos E; Kontopodis E; Hatzidaki D; Mavroudis D; Georgoulias V
Br J Cancer; 2009 Aug; 101(4):589-97. PubMed ID: 19623181
[TBL] [Abstract][Full Text] [Related]
13. Detection of circulating tumor cells in patients with breast cancer using the quantitative RT-PCR assay for monitoring of therapy efficacy.
Wang HY; Ahn S; Kim S; Park S; Park S; Han H; Sohn JH; Kim S; Lee H
Exp Mol Pathol; 2014 Dec; 97(3):445-52. PubMed ID: 25217799
[TBL] [Abstract][Full Text] [Related]
14. Cytokeratin-19 mRNA-positive circulating tumor cells after adjuvant chemotherapy in patients with early breast cancer.
Xenidis N; Ignatiadis M; Apostolaki S; Perraki M; Kalbakis K; Agelaki S; Stathopoulos EN; Chlouverakis G; Lianidou E; Kakolyris S; Georgoulias V; Mavroudis D
J Clin Oncol; 2009 May; 27(13):2177-84. PubMed ID: 19332733
[TBL] [Abstract][Full Text] [Related]
15. Detection of circulating tumor cells during follow-up of patients with early breast cancer: Clinical utility for monitoring of therapy efficacy.
Mikulová V; Cabiňaková M; Janatková I; Mestek O; Zima T; Tesařová P
Scand J Clin Lab Invest; 2014 Mar; 74(2):132-42. PubMed ID: 24350991
[TBL] [Abstract][Full Text] [Related]
16. Epithelial to mesenchymal transition markers expressed in circulating tumour cells of early and metastatic breast cancer patients.
Kallergi G; Papadaki MA; Politaki E; Mavroudis D; Georgoulias V; Agelaki S
Breast Cancer Res; 2011 Jun; 13(3):R59. PubMed ID: 21663619
[TBL] [Abstract][Full Text] [Related]
17. Detection of circulating tumor cells using manually performed immunocytochemistry (MICC) does not correlate with outcome in patients with early breast cancer - Results of the German SUCCESS-A- trial.
Jueckstock J; Rack B; Friedl TW; Scholz C; Steidl J; Trapp E; Tesch H; Forstbauer H; Lorenz R; Rezai M; Häberle L; Alunni-Fabbroni M; Schneeweiss A; Beckmann MW; Lichtenegger W; Fasching PA; Pantel K; Janni W;
BMC Cancer; 2016 Jul; 16():401. PubMed ID: 27387743
[TBL] [Abstract][Full Text] [Related]
18. Different prognostic value of cytokeratin-19 mRNA positive circulating tumor cells according to estrogen receptor and HER2 status in early-stage breast cancer.
Ignatiadis M; Xenidis N; Perraki M; Apostolaki S; Politaki E; Kafousi M; Stathopoulos EN; Stathopoulou A; Lianidou E; Chlouverakis G; Sotiriou C; Georgoulias V; Mavroudis D
J Clin Oncol; 2007 Nov; 25(33):5194-202. PubMed ID: 17954712
[TBL] [Abstract][Full Text] [Related]
19. Cytokeratin-19 mRNA-positive circulating tumor cells during follow-up of patients with operable breast cancer: prognostic relevance for late relapse.
Saloustros E; Perraki M; Apostolaki S; Kallergi G; Xyrafas A; Kalbakis K; Agelaki S; Kalykaki A; Georgoulias V; Mavroudis D
Breast Cancer Res; 2011 Jun; 13(3):R60. PubMed ID: 21663668
[TBL] [Abstract][Full Text] [Related]
20. Establishment of a multimarker qPCR panel for the molecular characterization of circulating tumor cells in blood samples of metastatic breast cancer patients during the course of palliative treatment.
Bredemeier M; Edimiris P; Tewes M; Mach P; Aktas B; Schellbach D; Wagner J; Kimmig R; Kasimir-Bauer S
Oncotarget; 2016 Jul; 7(27):41677-41690. PubMed ID: 27223437
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
